According to a recent study published in the June issue of Dermatologic Surgery, prescription Aldara (imiquimod) cream, 5% delivers long term clinical benefits in the treatment of actinic keratosis (AK), a precancerous skin condition caused by chronic sun exposure. Led by an investigator at the University of Minnesota, the study showed 75% of patients treated with Aldara Cream three times per week, and nearly 60% treated two times per week, continued to demonstrate complete clearance of AK after a follow‐up period of 12 to 18 months. The first immune response modifier (IRM) approved for AK, Aldara cream stimulates the skin's immune response, which may help decrease formation of recurrent or new AKs.
展开▼
